3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
4
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
9
Thoracic
7
Gynecologic
6
Other hematologic neoplasm
5
Genitourinary
5
Breast
5
Lymphoid
3
Tumor-Agnostic
2
Other solid neoplasm
2
Plasma cell
1
Head & Neck
1
Dermatologic
1
Conditions
Stomatitis
1
Multiple Myeloma
1
Lymphoma
1
Hematologic Neoplasms
1
Interventions
Dexamethasone
315
Bortezomib
166
Lenalidomide
132
pomalidomide
113
daratumumab
96
carfilzomib
69
Cyclophosphamide
44
Calcium Dobesilate
41
belantamab mafodotin
32
elotuzumab
31
fludarabine
27
ixazomib
24
isatuximab
21
Melphalan
21
venetoclax
18
selinexor
17
talquetamab
15
Prednisone
15
plerixafor
14
Panobinostat
14
Granulocyte Colony-Stimulating Factor
14
Injections
12
idecabtagene vicleucel
11
Zoledronic Acid
11
Thalidomide
11
Azacitidine
11
pembrolizumab
10
tocilizumab
9
nirogacestat
9
liposomal doxorubicin
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Saline Solution
×
Plasma cell
×
Clear all
NCT05493800
2024-05-29
Capella
MitoImmune Therapeutics
Phase 2
Unknown
60 enrolled